

**132nd MAINE LEGISLATURE****LD 1687****LR 2100(03)****An Act to Clarify and Increase Access to HIV Prevention Medications****Fiscal Note for Bill as Engrossed with:****C "A" (H-642)****Committee: Health Coverage, Insurance and Financial Services**

Fiscal Note

	FY 2025-26	FY 2026-27	Projections FY 2027-28	Projections FY 2028-29
Net Cost (Savings)				
General Fund	\$0	\$44,264	\$2,939	\$2,939
Appropriations/Allocations				
General Fund	\$0	\$44,264	\$2,939	\$2,939
Federal Expenditures Fund	\$0	\$146,951	\$31,183	\$31,183
Other Special Revenue Funds	\$0	\$1,609	\$3,218	\$3,218
Revenue				
Federal Expenditures Fund	\$0	\$146,951	\$31,183	\$31,183
Other Special Revenue Funds	\$0	\$1,609	\$3,218	\$3,218

Fiscal Detail and Notes

The bill includes ongoing General Fund appropriations to the Department of Health and Human Services of \$1,474 in fiscal year 2026-27 to provide reimbursement to pharmacists under the MaineCare program beginning January 1, 2027 for prescribing, dispensing and administering HIV prevention medications in an amount not to exceed a 60-day supply to an individual once every two years. The bill also includes a one-time General Fund appropriation to the department of \$42,974 in fiscal year 2026-27 for technology costs to implement the MaineCare reimbursement to pharmacists. Federal Expenditure Funds allocations are also included for matching funds and Other Special Revenue Funds allocations are included for drug rebates.

Any additional costs to the Department of Professional and Financial Regulation, Maine Board of Pharmacy to implement the provisions of this bill are expected to be minor and can be absorbed within existing budgeted resources.